NZ194445A - Monacolin k salts and esters - Google Patents

Monacolin k salts and esters

Info

Publication number
NZ194445A
NZ194445A NZ194445A NZ19444580A NZ194445A NZ 194445 A NZ194445 A NZ 194445A NZ 194445 A NZ194445 A NZ 194445A NZ 19444580 A NZ19444580 A NZ 19444580A NZ 194445 A NZ194445 A NZ 194445A
Authority
NZ
New Zealand
Prior art keywords
monacolin
monascus
sank
esters
monascus ruber
Prior art date
Application number
NZ194445A
Inventor
Y Tsujita
K Tanzawa
M Kuroda
S Iwado
K Humano
A Terahara
S Sato
Original Assignee
Sankyo Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from JP9581479A external-priority patent/JPS5621594A/en
Priority claimed from JP12346179A external-priority patent/JPS5646841A/en
Application filed by Sankyo Co filed Critical Sankyo Co
Publication of NZ194445A publication Critical patent/NZ194445A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40Unsaturated compounds
    • C07C59/42Unsaturated compounds containing hydroxy or O-metal groups
    • C07C59/46Unsaturated compounds containing hydroxy or O-metal groups containing rings other than six-membered aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C07C69/732Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids of unsaturated hydroxy carboxylic acids
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02EREDUCTION OF GREENHOUSE GAS [GHG] EMISSIONS, RELATED TO ENERGY GENERATION, TRANSMISSION OR DISTRIBUTION
    • Y02E50/00Technologies for the production of fuel of non-fossil origin
    • Y02E50/10Biofuels, e.g. bio-diesel

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Description

1944 4 5 wort* omsymv+to* -7?- • • Complet© Specification FiS6d:°&".7;#P cimtyfcFWPXffitf&M4!} RblK 3j/&or23 ■ Publication i?ots: P.O. Josmsi, Wo: Patents Form No. 5 NEW ZEALAND PATENTS ACT 1953 COMPLETE SPECIFICATION MONACOLIN K DERIVATIVES SANKYO COMPANY, LIMITED., a Japanese company, of 1-6, 3-Chome, Nihonbashi Eoncho, Chuo-ku, Tokyo, Japan, hereby declare the invention, for which /I/we pray that a patent may be granted to jate/us, and the method by which it is to be performed, to be particularly described in and by the following statement (if®8tewa4 fcy pag* I A,) 194445 ifl The present invention relates to salts and esters of the free acid corresponding to the lactone Monacolin K, to processes for their preparation and to their use as anti-hypercholesteraemic agents.
New Zealand Patent Specifica,tion No. 192919, describes and claims the compound Monacolin K and its preparation by microorganisms of the genus llonascus, especially Mp.p«scus ruber strain 1005 {FERM 4822). In thi^ specification, the valuable and unexpected 10 activity of the compound Monacolin K as an anti- Subsequently, there has been disclosed the preparation of Monacolin K by the cultivation of a variety of other microorganisms of the and esters of the free acid of which Monacolin K is the lactone have an anti-hypercholesteraemic activity of the same type as Monacolin K but to a comparable or ' greater degree. For convenience, these compounds are 20 hereinafter referred to as "Monacolin K salts or esters" and it will be understood that this expression refers to the salts and esters of the acid of which Monacolin K is the lactone. agent is disclosed. genus Monascus. We have now found that the salts 1944 4 5 2.
The Monacolin K salts and esters provided by the present invention have the formula: COO(R), in which: R represents a substituted or unsubstituted alkyl group or a metal atomj and _n is the reciprocal of the valency of the group or atom represented by R.
The invention also provides a process for preparing Monacolin K salts and esters by the salification or esterificatian of Monacolin K or a reactive derivative thereof.
The invention still further provides a I 94445 3. process for preparing Monacolin K salts and esters by first _ cultivating a Monacolin K-producing microorganism of the genus Monascus in a culture medium therefor .and separating Monacolin K starting material from the culture medium and then converting the starting material into a Monacolin K salt or ester.
The Monacolin K salts to which' the present invention applies are metal salts and preferably: alkali metal salts, such as sodium or potassium salts; alkaline earth metal salts, such as the calcium or magnesium salts; salts of metals from Group Ilia 10 of the Periodic Table of the Elements, such as the aluminium salt; and salts of transition metals fronT Groups lb, Ufa and VIII of the Periodic Table of the Elements, such as the iron, nickel, cobalt, copper and zinc salts. Of these metal salts, the 15 alkali metal salts, alkaline earth metal salts and aluminium salt are preferred and the sodium, calcium and aluminium salts are most preferred.
Monacolin K. salts can readily be converted to Monacolin K itself or to the parent acid of 20 Monacolin K by acidification. The resulting Monacolin K. . or acid will revert to a salt in the presence of an alkali e.g. an alkali metal hydroxide or carbonate. 3 19AUGJ982 RECEIVED 194445 4.
This exchange can be carried out quantitatively and repeatedly. We- have found that conversion between Monacolin K or its parent acid and the metal salt is closely related to the pH of the medium containing 5 them. The critical pH value is about 5.0.
Provided that metal ions are available, the Monacolin K is always present in the form of a salt when the pH is above 5.0. On the other hand, where the pH is below 5.0, Monacolin K itself, the parent acid 10 of Monacolin K or a mixture of the two in varying ratios will be present.
The Monacolin K. esters provided by the present invention are those compounds having the above formula in which R represents a substituted or 15 unsubstituted alkyl group. Where R represents an unsubstituted alkyl group, it may be a straight or branched chain group preferably having up to fl carbon atoms. Examples of such alkyl groups represented by R include the methyl, ethyl, propyl, 20 isopropyl, butyl and hexyl groups.
Where R represents a substituted alkyl group, the substituent may, as is well-known in this art, be selected from a wide range of groups and 194445 . atoms, including aryl groups, acyl groups (especially arylcarbonyl groups), alkoxy groups, halogen atoms and hydroxy groups. Particularly preferred sub-stituents are aryl groups and arylcarbonyl groups, that is to say R represents an aralkyl group or an arylcarbonylalkyl group.
Where R represents an aralkyl group, it is preferably a substituted or unsubstituted benzyl group. Substituted benzyl groups preferably have one or more substituents selected from alkyl groups, alkoxy groups and halogen atoms. Examples of such benzyl groups include the benzyl, 2-methylbenzy1, 3-methylbenzyl, 4-methylbenzy1, 2-ethylbenzy1, 3-ethylbenzyl, 4-ethylbenzy1, 2-methoxybenzyl, 3-methoxybenzy1, 4-methoxybenzy1, 2-ethoxybenzy1, 3-ethoxybenzyl, 4-ethoxybenzy1, 2-chlorobenzy1, 3-chlorobenzyl, 4-chlorobenzyl, 2-bromobenzy1, 3-bromobenzy1 or 4-bromobenzyl groups.
Where R represents an arylcarbonylalkyl group, it is preferably a substituted or unsubstituted phenacyl group. Substituted phenacyl groups preferably 194445 6. have one or more substituents selected from alkyl groups, alkoxy groups and halogen atoms. Examples of such phenacyl groups include/the phenacyl, 2-methyl-pfienacyl, 3-methylphenacyl, 4-methylphenacyl, 5 2-ethylphenacyl, 3-ethylphenacyl, 4-ethy lphenacyl, 2-methoxyphenacyl, 3-methoxyphenacy 1, 4-methoxy-phenacyl, 2-ethoxyphenacyl, 3-ethoxyphenacyl, 4-ethoxyphenacyl, 2-chlorophenacyl, 3-chlorophenacy1, 4-chlorophenacyl, 2-bromophenacyl, 3-bromophenacy1 10 or 4-b.romophenacyl groups.
Of the esters, we particularly prefer the methyl, ethyl, butyl and benzyl esters.
The Monacolin K salts and esters of the present invention may readily be prepared by salifi-15 cation or esterification of Monacolin K itself or of a reactive derivative of Monacolin K. Examples of suitable reactive derivatives include the parent acid of Monacolin K and, in the case of the preparation of esters, Monacolin K salts Ce.g. those classes of .20 salt described above, especially the sodium,. potassium, calcium, magnesium, aluminium, iron, zinc, copper, nickel or cgbalt salt). , 194445 * Monacolin K salts may be prepared by simple reaction of Monacolin K or its parent acid with an oxide, hydroxide, carbonate or bicarbonate, preferably a hydroxide or carbonate, of the chosen metal. Care should be taken to ensure that the reaction is carried out at a pH value exceeding 5.0 and preferably exceeding 7.0 to ensure complete conversion of the Monacolin K or acid to the desired salt. The Monacolin K employed In this reaction will preferably be prepared, as described in our aforementioned specification, by cultivation of a fungus of the genus Monascus and isolation of Ronacolin K from the culture medium. The Monacolin K may be subjected to isolation from the culture medium and purification prior to salification or, more preferably, the salification reaction is effected in the course of the isolation and purification of Monacolin K. from the culture medium, so that the Monacolin K. is isolated In the form of its desired metal salt. Whichever method is adopted, the metal salt may be isolated from the reaction medium or the culture medium by methods well-known in the art, including those hereafter described in connection with the isolation of Monacolin K. metal salts from cultures of Monacolin K. salt-producing 8. 194445 Monacolin K esters may be prepared by simple esterification of Monacolin K or a reactive derivative thereof. The reaction may be carried out by reacting an alcohol of formula ROH Cor a reactive derivative 5 thereof) in which R represents a substituted or unsub-stituted alkyl group with Monacolin K or its parent acid, preferably in the presence of a dehydrating ageht, e.g. an acid halide, such as acetyl chloride. Alternatively, the Monacolin K esters may be prepared by 10 reacting a Monacolin K salt with a halide of formula RX Cin which R represents a substituted or unsub-stiti|ted alkyl group and X represents a halogen atom, preferably an iodine atom).
Ti" ir iilnn ponnih") r—Lu yn. Monoeolin K w 1 tic directly by the cultivation of q Monoeolin K at "Hi fun Aiming mioroorganiom of the genua Monaocup in a culture medium thorofor—and coparating the. Monoeolin K eaW: from the culture medium. Suitable microorganisms which can be used in the process of producing Monacolin K include: Monascus arika SANK 10171 CIFO 6540)j Monascus purpurous SANK 10271 CIFO 4513)j Monascus ruber SANK 10671 20 CFerm 4958)j Monascus vit re us SANK 10960 (NIHS 609, e-609; Fer/u 4960); Monascus paxi i SANK 11172 (IF0 8201)j Monascus ruber SANK 11272 CIFO 9203)j Monascus ruber ; > SANK 13778 CFerm 4959)j Monascus ruber SANK 15177 CFerm 4956)j Monascus ruber SANK 17075 CCBS 832.70)j 25 Monascus ruber SANK 17175 CCBS 503.70)j Monascus ruber S&Z. PATENT OFFICE ■imiijnw mi i ^| £ 19 AUG 3982 I RPCflVeD • "■" 9. 194445 SANK. 17275 CATCC 18199]j and Monascus ruber SANK 18174 CFerm 4957). All of these microorganisms are available from recognized culture collections, as indicated by the following codes: 5 IFO = Institute for Fermentation, Osaka, Japan j Ferm = Fermentation Research Agency of Industrial S Technology, Ministry o 10 national Trade and Ind Institute, cience and f Inter-ustry, Japanj NIHS = National Sciences CBS = Centraal Bureau voor Schimmel- cultures, Netherlands; ' ATCC = American Type Culture Collection, Maryland, U.S.A..
Preferred Monacolin K-producing microorganisms of the genus yonascus which may be ysed in the process of the invention to produce i Monacolin K salts are Monascus ruber SANK 10671, 20 Monascus ruber SANK 11272, Monascus ruber SANK 13778, Monascus ruber SANK 15177 and Monascus ruber SANK 18174. • Institute of Hygenic , Japanj 194445 .
Monascus ruber SANK 10671, Monascus ruber SANK 13778, • Monascus ruber SANK 15177 and Monascus ruber SANK 18174 are all fungi recently isolated from soil by the present inventors and their microbiological 5 properties are given below: Monascus ruber SANK 15177 (FERM 4956) This strain was isolated from soil at Tukimino, Yamato-city, Kanagawa-prefecture, Japan and was deposited on 27 April 1979 under the accession No. 4956 with the said Fermentation Research Institute.
The strain grows well on a potato-glucose-agar medium at 25°C and produces a soluble colouring material having a yellowish-brown to reddish-brown colour in the medium. It forms many cleistothecia on the basal layer of hyphae.
On oatmeal agar medium, it produces a pale brown colouring material and grows well. Formation of cleistothecia is good and the cleistothecia are spherical, of diameter 30 - 60 microns and formed on short stalks. These stalks are nearly colourless ancj branched and of size 25 - 60 x 3.5 - 5.0 microns. The asci. are evanescent and thus difficult to observe. 19444 5 11.
The ascospores are colourless and ellipsoid and their dimensions are 4.5 - 6.5 x 4.0 - 5.0 micronsj their surfaces are smooth. The conidia are linked basipetally and are of size 7.0 - 10.0 x 6.0 - 10.0 microns.
Their tissues are disrupted.
Although the strain will grow at 37°C, best growth is observed between 23 and 30°C.
Monascus.Ruber SANK 10671 CFERM 4956) This strain was isolated from soil at Shinagawa-ku, Tokyo, Japan and was deposited on 27 April, 1979 with the said Fermentation Research Institute under the accession No. 4958.
Growth on potato-glucose-agar and oatmeal agar media is similar to that of strain SANK 15177, except that the soluble colouring matter produced is dark red. The diameter of the cleistothecia is 30 - 80 microns and the dimensions of the stalks are 30 - 70 x 3.0 - 5.0 microns. Asci are not observed. The ascospores are colourless and ellipsoid and their dimensions are 4.5 - 6.5 x 4.0 - 5.0 microns. The conidia are colourless and pyriform or ovoid and their dimensions are 6.0 - 10.0 x 6.0 - 8.5 microns. 1 944.4 5 12.
Monascus ruber SANK 13778 (FERM 4959) This strain was isolated from soil at Inawashiro- cho, Nagata, Yama-gun, Fukushima-prefecture, Japan and was deposited on 27 April 1979 under the accession No. 4959 with the said Fermentation Research Institute.
Growth on potato-glucose-agar and oatmeal agar media is similar to that of strain SANK 15177, except that the soluble colouring material produced is a pale reddish-brown to reddish-brown colour. The cleisto-10 thecia are of diameter 35 - 75 microns and the stalks are 30 - 70 x 3.5 - 5.0 microns. Asci are not observed. The ascospores are colourless and ellipsoid and their dimensions are 4.5 - 6.0 x 4.0 - 5.0 microns; their surfaces are smooth. The dimensions of the conidia 15 are 7.0 - 10.0 x 6.0 - 10.0 microns, Monascus ruber SANK 18174 (FERM 4957) t ————— This strain was isolated from soil at Shakotan-cho, Shakotan-gun, Shiribeshi Shicho, Hokkaido-prefecture, Japan and was deposited on 27 April, 1979 20 with the said Fermentation Research Institute under the accession No. 4957.
Growth on potato-glucose-agar and oatmeal agar 194445 13 • media is similar to that of strain SANK 15177, except that the colouring material produced is pale pink. The cleistothecia are of diameter 20 - 70 microns and the dimensions of the stalks are 20 - 60 x 3.0 - 5.0 microns. Asci are not observed. The ascospores are colourless and ellipsoid and their dimensions are 5.0 - 7.0 x 4.0 - 5.5 micronsj their surfaces are smooth. The conidia are linked together basipetally and are colourless and most of them are pyriform and of dimensions 6.0 - 9.5 x 6.0 - 10.0 microns.
Based on the observations of their characteristics uas reported above, these microorganisms were all identified as strains of Monascus ruber van Tieghem.
Microbiological properties of Monascus ruber have been reported in the following literature: Takada, Transactions of the Micological Society of Japn, _9, 125 - 130 (1969) [Materials for the Fungus Flora of Japan (7)] and van Tieghem, Bull. Soc. Botan.
France, 3_1_, 227 (1884). Ascospore generation of the strain has been reported by Cole ^t £1^ in the Canadian Journal of Botany, 46_, 987 (1968), "Conidium ontogeny in hyphomycetes. The imperfect state of Monascus ruber and its meristem arthrospores". 14. 194445 Apart from the strains of fungus mentioned above, any fungi of the genus Monascus, including varieties and mutants, which are capable of producing Monacolin K starting material may be employed in the process of the present invention.
Monacolin K starting material may be produced by cultivating the chosen Monacolin K-producing microorganism of the genus Monascus in a culture broth under aerobic conditions, using the same techniques as are well-known in the art for the cultivation of fungi and other microorganisms, and separating Monacolin K starting material from the culture medium. For example, the chosen strain of Monascus may first be cultivated on a suitable medium and then the produced microorganisms may be collected and innoculated Into and cultivated on another culture medium to produce the desired Monacolin K starting material, the culture medium used for the multiplication of the microorganism and the culture medium used for the production of the Monacolin K starting material may be the same or different. Any culture medium well-known in the art for the cultivation of fungi may be employed, provided that it contains, as is well-known, the necessary nutrient materials, especially an assimilable carbon source and an assimilable nitrogen source. Examples of suitable sources of assimilable carbon are glucose, maltose, dextrin, starch, lactose, sucrose and glycerine. Of these sources, glucose and glycerine are particularly preferred for the . '94445 production of Monacolin K starting material. Examples of suitable sources of assimilable nitrogen are peptone, meat extract, yeast, yeast extract, soybean meal, peanut meal, corn steep liquor, rice bran and inorganic nitrogen sources. Of these nitrogen sources, peptone is particularly preferred. When producing—Llie fluiidL'ulJ^i K salt, an inorganic salt and/or a metal salt may^if necessary, be added to the culture mediptru Furthermore, if necessary, a minor amourj^of a heavy metal may also be added. In the D^cfauction of Monacolin K salts by fermentation witb^a fungus of the genus Monascus, it is important^fefiat there should be present in the culture me d i urp^-dr within the body of the fungus metal ions forrccponding to the metal—s-alt which it—is—desired to »—« «—I»«-|JTTJ (J LJ U C » We porticularly prefer that the iriicroorgnni^ji'i should first be sub-cultured on a potajtJ>~"d,£xtrose-agar medium (e.g. a product ojf^-B-rfco Company) and then i nnoculated^ifrtoand cultivated on another culture frrggTum to produce the—dosirod Honaoolin K co-3rt-.— The microorganism is preferably cultivated under aerobic conditions using cultivation methods well-knowp in the art, for example solid culture, shaken culture or culture under aeration and agitation. The micro- .^7? fO V RECEIVED *L 194445 16. organism will grow over a wide temperature range, e.g. from 7 to 35°C, but, especially when the microorganism is grown for the purpose of producing Monacolin K starting material, the more preferred cultivation temperature is within the range of 20 to 30°C.
During the cultivation of the microorganism, the production of the Monacolin K starting material may be monitored by sampling the culture medium and measuring the physiological activity of the Monacolin K starting material in the culture medium by the tests described hereafter. Cultivation may then be continued until a substantial accumulation of Monacolin K starting material has been achieved in the culture medium, at which time the Monacolin K starting material may then be isolated and recovered from the culture medium and the tissues of the microorganism by any suitable combination of isolation techniques, chosen having regard to its physical and chemical properties. For example, any or all of the following isolation techniques may be employed: extraction of the liquor from the culture 20 broth with a hydrophilic solvent [such as diethyl ether, ethyl acetate or chloroform)j extraction of the organism with a hydrophilic solvent Csuch as acetone or an alcohol)j concentration, e.g. by evaporating off all or part of the solvent under reduced pressure? dissolution into a 25 more polar solvent Csuch as acetone or an alcohol); 17. '94445 removal of impurities with a less polar solvent (such as petroleum ether or hexanejj gel filtration through a column of a material such as Sephadex (a trade name for a material available from Pharmacea Co. Limited, U.S.A.); absorptive chromatography with active carbon or silica gel; rapid liquid chromatography; conversion to a Monacolin K salt and direct purification in the form of the metal salt; and other similar methods. By using a suitable combination of these techniques, the desired Monacolin K starting material or salt can be isolated from the culture broth as a pure substance.
As. fi&&ef4-brgd~~in our atorementTi specification, J^^veirOTrnlK itself may also be produced uSrirtfg the rwicrerorgarri^ms and—fe-ochniqu—doDcribcd—obovo.— The physiological activity of Monacolin K salts and esters can be assayed and determined quantitatively by the following tests, which can also be employed, in modified form, to monitor the production of Monacolin K starting material in the course of the fermentation process of the present invention. ^ / 1. Inhibition of cholesterol biosynthesis Like Monacolin K itself, Monacolin K salts and 19 AUG 3982 1 1944 18. esters specifically inhibit the activity of 3-hydroxy-3-methylglutaryl-CoA reductase, which is the rate-determing enzyme in the biosynthesis of cholesterol. The following Table 1 gives the concentrations (in ng/ml) of the compounds of the invention inhibiting the 5 activity of 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase by 50% [as measured by the method described in Analytical Biochemistry, _31_, 383 (1969)] and the concentrations Cin ng/ml) of the compound of the invention inhibiting cholesterol biosynthesis by 50% [as measured by the method 10 of the Journal of Biological Chemistry, 247, 4914 [1972)]. Also given are the corresponding results'for the known compounds ML-236B Cwhich is a compound known to have a similar type of activity and produced by cultivating microorganisms of the genus Penici11ium, as disclosed in 15 . our United Kingdom Patent Specification No. 1,453,425). Also given is the concentration of Monacolin K itself which inhibits cholesterol biosynthesis by 50%. It will be seen that, whereas the concentration of ML-236B required to inhibit cholesterol biosynthesis by 50% is 20 10.0 ng/ml, the corresponding concentration for the Monacolin K esters is of the order of 1 ng/ml Ci.e. about 10 times better) and the corresponding concentration for the sodium salt of Monacolin K is about 0.14 ng/ml (i.e. about 70 times better). The activities of the salts and 25 esters of Monacolin K are comparable with or better than 1944 * 19. that of Monacolin K itself.
Table 1 Concentration (ng/ml) required to inhibit by 50% Compound HMG-CoA cholesterol reductase biosynthesis methyl ester 70.0 1 .2 ethyl ester 12.0 1.3 butyl ester .0 2.0 benzyl ester 11.0 1 .1 sodium salt 2.0 0.14 calcium salt 12.0 1.0 Monacolin K 2.0 ML - 236B .0 .0 1944 4 S . 2. Reduction in blood cholesterol levels The animals used in this test were rats of the Wistar Imamichi strain, each having a body weight of about 300 g. The tests were conducted on groups of 5. rats, each group consisting of 5 animals. Each animal was intravenously injected with 400 mg/kg of Triton WR-1339 (a trade name for a material known to increase the blood cholesterol level) whilst simultaneously administering orally one of the compounds shown in 10 following Table 2 in the amount shown in that Table. hours after oral administration, the rats were sacrificed by bleeding and the blood and livers were collected and their cholesterol levels were determined by conventional means. The results are reported in Table 2, which gives the reduction in blood and liver cholesterol levels compared with a control group of rats to which Triton WR-1339 alone had been administered.
For purposes of comparison, the corresponding results are given for Monacolin K itself and for ML-236B, 20 but these compounds were administered in doses substantially greater than those used for the compounds of the invention in order to achieve a comparable reduction in cholesterol levels. 1944 4 21.
Table 2 Compound Dose mg/kg Reduction in cholesterol levels (%) in the blood liver methyl ester 23.8 18.4 ethyl ester 23.3 18.0 butyl ester 19.5 .7 benzyl ester 24.4 18.5 sodium salt. 2 27.5 18.9 calcium salt 21.4 17.1 Monacolin K 22.4 16.7 ML-236-B 40 24.6 .9 The reduction in blood or liver cholesterol level was given by the formula: 1 - (C - B) x 100 A - B where: A = level in group treated only with Triton WR-1339i B = level in untreated control group; C = level in test group. 194445 22. 3 . Acute toxicity The compounds tested were the methyl, ethyl, butyl and benzyl esters and sodium and calcium salts of Monacolin K. It was found that the 50% lethal dose (LDgg) of each of these compounds was at least 2000 mg/kg on oral administration and at least 500 mg/kg on intraperitoneal administration. The compounds thus have a very low toxicity.
These results demonstrate that the compounds of 10 the invention inhibit the biosynthesis of cholesterol and, as a result, lower cholesterol levels in blood.
They are thus valuable medicines in the treatment of hyper-lipaemia and arteriosclerosis.
The compounds of the invention may be administered 15 orally or parenterally in the form of a capsule, tablet, injectable preparation or any other known formulation, although we normally prefer to administer them orally. The dose will vary, depending upon the age and body weight of the patient and the severity of the condition, but, 20 in general, the daily dose for an adult is preferably from 0.1 to 100 mg, more preferably from 0.1 to 10 mg, " in the case of Monacolin K salts and from 0.5 to 100 mg, more preferably from 0.5 to 10 mg, in the case of Monacolin 1944 4 'f 23.
K esters.
The preparation of the compounds of the invention is further illustrated by reference to the following Examples.
EXAMPLE 1 Sodium salt of Monacolin K 300 litres of a culture medium having a pH of 5.5 before sterilization and containing 5% w/v glucose, 0.5% w/v corn steep liquor, 2% w/v peptone CKyokuto brand, 10 available from Kyokuto Seiyaku K.K, Japan) and 0.5% w/v ammonium chloride was charged into a 600 litre fermentqr and innoculated with the organism Monascus ruber SANK 18174 CFerm. 4957). Cultivation of the organism was effected for 116 hours at 26°C with an aeration rate of 15 300 litres per minute and agitation at 190 revolutions A per minute. At the end of this time, the pH of the culture broth containing the organism was adjusted to a value of 3.4 by the addition of 6N hydrochloric acid and then the broth was extracted with 800 litres of 20 methanol. 6 kg of Hyflo Super Cel were added and then the 19 44 24. extract was filtered, using a filter press, to give 1100 litres of methanol^ extract. This extract was washed with 200 litres of a saturated aqueous solution of sodium chloride and then with 180 litres of ethylcyclo-5 hexane. The resulting solution was extracted with BOO litres of ethylene dichloride. 50 g of trifluoro-acetic acid were added to the ethylene dichloride extract and allowed to react at 80°C for 30 minutes. The reaction mixture was then washed successively with 200 10 litres of a 2% w/v aqueous solution of sodium bicarbonate and with 200 litres of a 10% w/v aqueous solution of sodium chloride. The mixture was then concentrated by evaporation under reduced pressure to give 135 g of an oily substance.
This oily substance was dissolved in 400 ml of methanol. 20 ml of the resulting methanolic solution (containing 6.8 g of the oil) were then subjected to preparative rapid liquid chromatography using a Waters Co. Limited System 500 equipped with a Prepac C^g column 20 [reversed phase column). A 85 : 15 by volume mixture of methanol and water was used as the developer.
Development was carried out at a flow rate of 200 ml/minute [developing time about 10 minutes), watching a differential refTactometer connected to the body and the fraction 25 showing the main peak on the differential refTactometer 194445 . was separated. This operation was repeated and the resulting main peak fractions were collected and concentrated to give 10.2 g of an oily substance. This oily substance was dissolved in. 30 ml of methanol, and 5 6 ml of the methanolic solution (containing about 2 g of the oil) were subjected again to the same preparative rapid liquid chromatography and developed with a 80 : 20 by volume mixture of methanol and water at a flow rate of 200 ml/minute. The fraction showing the 1Q main peak was separated. This operation was repeated and the main peak fractions were collected and concentrated. The residue was treated with aqueous methanol to give 1170 mg of crude crystals, which were recrystallized several times from ethanol to give 864 mg of crystals.
To these crystals were added 19.4 ml of 0.1N aqueous sodium hydroxide and the mixture was stirred at 50 - 60°C for 3 hours. Insolubles were filtered off and the filtrate was lyophilized to give 900 mg of the sodium salt of Monacolin K having the following properties: 1. Colour and form: White powder. 2. Elemental analysis: Calculated: C, 64.84%j H, 8.38%j Found: C, 64.78%, H, 8.55%; Na, 5.17%. Na, 5.21%. 1944 4 26 .
Molecular weight: 444 [by mass spectrometry (F.D. Mass.)].
Molecular formula: C24H37°6Na" Ultraviolet absorption spectrum: As shown in Figure 1 of the accompanying drawings, X : 6 max 232 nm Clog e = 4.30); 239 nm Clog e = 4.36); 248 nm Clog e =4.19).
Infrared absorption spectrum (KBr pellet): As shown in Figure 2 of the accompanying drawings.
Nuclear magnetic resonance spectrum CD2O): Aa shown in Figure 3 of the accompanying drawings.
Rapid liquid chromatography: Holding time : 8.5 minutes; Column, Microbondapac C18; 60% v/v aqueous methanol + 0.1% PIC-A (a product of Waters Co. Limited); 1944 4 5 27.
Flow rate, 1.5 ml/minute.
As shown in Figure 4 of the accompanying drawings.
Solubility: Soluble in waterj insoluble in organic solvents.
Specific rotation: [a] ^ = +266° Cc = 0.33, water).
EXAMPLE 2 Sodium salt of Monacolin K 300 litres of a culture medium having a pH of 7.4 before sterilization and containing 1.5% w/v soluble starch, 1.5% w/v glycerine, 2,0% w/v fish meal and 0.2% w/v calcium carbonate were charged into a 600 litre fermenter and innoculated with the organism Monascus ruber SANK 17075 CCBS 032.70). Cultivation of the organism was effected for 120 hours at 26°C with an aeration rate of 300 litres per minute and agitation at '190 revolutions per minute. The culture broth was then filtered using a filter press, to give 35 kg Cwet weight) of the organism. 9. . 1944 4 5 28.
To this were added 100 litres of water and the pH value of the mixture was adjusted to 12 by addition of sodium hydroxide with stirring. The mixture was then left at room temperature for 1 hour, after which 2 kg of 5 Hyflo Super Cel were added to the mixture, which was then filtered using a filter press. The pH of the filtrate was adjusted to a value of 10 by the addition of hydrochloric acid, and the resulting mixture was then adsorbed on a column containing 5 litres of HP-20 resin 10 washed with 15 litres of each of water and a 10% v/v aqueous solution of methanol. The column was then eluted with 90% v/v aqueous methanol. The eluate was concentrated to a volume of about 10 litres and then its pH was adjusted to a value of 2 by addition of hydro-15 chloric acid and the mixture was extracted with ethyl acetate. The extract was washed with a saturated aqueous solution of sodium chloride, dried over anhydrous sodium sulphate and then concentrated by evaporation to dryness to give 50 g of an oily substance containing 20 Monacolin K acid. To this oily substance was added sufficient methanol to give a total volume of 100 ml*. 20 ml of the resulting solution were subjected to preparative rapid liquid chromatography using a reversed phase column Cas described in Example 1), eluted with a 20% v/v aqueous 25 solution of methanol Ccontaining 2% acetic acid) at a flow rate of 200 ml/minute. The fraction showing the 1944 4 5 29. main peak on the differential refTactometer was separated C7 - 10 minutes]. The remaining 80 ml of the methanolic solution was then treated by the same procedure. The resulting main peak fractions were collected, concentrated 5 and extracted with ethyl acetate. The extract was concentrated to dryness after adding heptane, to give 1.2 g of an oily substance.
This oily substance was dissolved in 20 ml of methanol and then subjected to rapid liquid chromatography 10 as described above to give 150 mg of Monacolin K acid. To this were added 2 ml of methanol and 100 ml of water and the resulting solution was adjusted to a pH of 8.0 by addition of 1N aqueous sodium hydroxide to give a clear aqueous solution. This solution was passed 15 through a column containing 10 ml of HP-20 resin and then the column was washed with 100 ml of water and eluted with 80% v/v aqueous methanol. The eluate was lyophilized to give 130 mg of the sodium salt of Monacolin K in the form of a white powder. The properties of the product 20 were identical with those reported for the product of Example 1. 1944 4 5 .
EXAMPLE 3 Calcium salt of Monacolin K The cultivation, extraction, concentration, preparative rapid liquid chromatography and recrystal-5 lization from ethanol described in Example 1 were repeated. 500 mg of the resulting crystals were then dissolved in 50 ml of methylene chloride and the resulting solution was filtered through a millipore filter. 20 ml of a saturated aqueous solution of calcium hydroxide were 10 added to the filtrate and then the mixture was vigorously stirred at room temperature. Whenever the pH of the solution decreased to a value below 8, a further 10 ml portion of a saturated aqueous solution of calcium hydroxide was added and stirring was continued. When the 15 pH no longer decreased Cafter a total of 50 ml of the aqueous solution of calcium hydroxide had been added), distilled water was added and the whole solution was placed into a separating funnel. The organic phase was collected and the solvent was distilled off. The residue 20 was worked up with heptane and then a powder was obtained by subjecting the mixture to ultrasonic waves. The powder was filtered and dried to give 450 mg of the calcium salt of Monacolin K in the form of a white powder.
This calcium salt had the following properties: 194445 31 .
Molecular weight: 682 Cby mass spectrometry).
Molecular formula: (C24H37G612*Ca Melting point: 155 - 155°C twith decomposition) Specific rotation: [a]^5 = +209° Cc = 1.48, chloroform).
Infrared absorption spectrum CKBr): As shown in Figure 5 of the accompanying drawings. .
Nuclear magnetic resonance spectrum CCD^OD): As shown in Figure 6 of the accompanying drawings.
EXAMPLE 4 Methyl ester o.f Monacolin K The cultivation, preparative rapid liquid extraction, concentration, chromatography and recrystalli- 1944 4 5 32. zation from ethanol procedures described in Example 1 were repeated to give 864 mg of Monacolin K. 200 mg of this Monacolin K were dissolved in 20 ml of methanol Cwhich had previously been dehydrated with Molecular 5 Sieve 3A). After adding a few drops of acetyl chloride, the solution was stirred at room temperature for. 3 hours. The solvent was distilled off and the residue was extracted with 50 ml of ethyl acetate. The extract was washed in turn with a 2% w/v aqueous solution of 10 sodium bicarbonate and a saturated aqueous solution of. sodium chloride and then dried over anhydrous sodium sulphate, after which the solvent was distilled off. The residue was adsorbed on a column containing 10 g of silica gel CWakogel C-100) which had previously been 15 treated with benzene. The fractions eluted with a 6 : 94 by volume mixture of ethyl acetate and benzene were collected and the solvent was distilled off to give 65 mg of the methyl ester of Monacolin K as a colourless oil.
This product had the following properties: 1. Molecular weight: 436.6 Cby mass spectrometry). 2.
Molecular formula: 19.44 4 33.
C25H4Q°6* Specific rotation: [a] ^ = +200° Cc = 1.05)# methanol. 4. Infrared absorption spectrum: As shown in Figure 7 of the accompanying drawings.
. Nuclear magnetic- resonance spectrum: As shown in Figure 0 of the accompanying drawings.
EXAMPLE 5 Methyl ester of Monacolin K The sodium salt of Monacolin K. was prepared as described in Example 2. 100 mg of this sodium salt were then dissolved in 2 ml of dimethyl sulphoxide and then 15 50 jil of methyl iodide were added to the solution. The solution was then refluxed, with'stirring, at 40 - 50°C for 5 hours in a reactor equipped with a reflux condenser. The reaction mixture was then diluted with 5 ml of water and extracted with 10 ml of methylene chloride. The 20 solvent was distilled from the extract' and the residue was <1 94445 34. adsorbed on a column containing 10 g of silica gel (Wakogel C-100) which had previously been treated with benzene. The fractionseluted with a 4 : 96 by volume mixture of ethyl acetate and benzene were collected and 5 the solvent was distilled off to give 35 mg of the methyl ester of Monacolin K in the form of an oil.
EXAMPLE 6 Ethyl ester of Monacolin K. 100 mg of Monacolin K (prepared as described 10 in Example 1) were dissolved in 15 ml of ethanol which had previously been dehydrated with Molecular Sieve 3A and a few drops of acetyl chloride were added to the solution. The mixture was then stirred at room temperature for 3 hours, after which the solvent was 15 distilled off and the residue was extracted with 50 ml of ethyl acetate. The extract was washed, in turn, with a 2% w/v aqueous solution of sodium bicarbonate and a saturated aqueous solution of sodium chloride and then dried over anhydrous sodium sulphate. After distilling 20 off the solvent, the residue was adsorbed on a column containing 10 g of silica gel (Wakogel C-100) which had previously been treated with benzene. The fractions eluted with a 6 : 94 by volume mixture of ethyl acetate 19444 5 . and benzene were collected and the solvent was distilled off to give 30 mg of the ethyl ester of Monacolin K in the form of a colourless oil.
The properties of this compound were as follows; 1. Molecular weight: 450.6 Cby mass spectrometry). 2. Molecular formula: C26H42°B* 3. Infrared 'absorption spectrum CCHCl^) : As shown in Figure 9 of the accompanying drawings. 4. Nuclear magnetic resonance spectrum CCDCl^): As shown in Figure 10 of the accompanying drawings.
EXAMPLE 7 Butyl ester of Monacolin K 200 mg of Monacolin K [prepared as described in Example 1) were dissolved in 20 ml of butanol, which had 19444 36 . previously been dehydrated with Molecular Sieve 3A.
After adding a few drops of acetyl chloride to the solution, the resulting mixture was stirred at room temperature for 2 hours. The solvent was then distilled 5 off and the residue was extracted with 50 ml of ethyl acetate. The extract was washed, in turn, with a 2% w/v aqueous solution of sodium bicarbonate and a saturated aqueous solution of sodium chloride. The solution was then dried over anhydrous sodium sulphate and the solvent 10 was distilled off. The residue was adsorbed on a column containing 10 g of silica gel (Wakogel C-100) which had previously been treated with benzene. The fractions eluted with a 4 : 96 by volume mixture of ethyl acetate and benzene were collected and the solvent was distilled 15 off to give 00 mg of the butyl ester of Monacolin K in the form of a colourless oil.
This compound had the following properties: 1. Molecular weight: 478.7 (by mass spectrometry). 2. Molecular formula: C28H46°6" 3. Infrared absorption spectrum (CHCl^): rt. '* 19444 37.
As shown in Figure 11 of the accompanying drawi ngs.
Nuclear magnetic resonance spectrum (CDCl^): As shown in Figure 12 of the accompanying drawi ngs.
EXAMPLE 8 Benzyl ester of Monacolin K, 200 mg of Monacolin K (prepared as described in Example 1) were dissolved in 20 ml of benzyl alcohol 10 which had previously been dehydrated with Molecular Sieve 3A. After adding a few drops of acetyl chloride to the solution, the resulting mixture was stirred at room temperature for 3 hours. The solvent was then distilled off and the residue was extracted with 50 ml 15 of ethyl acetate. The extract was washed with, in turn, a 2% w/v aqueous solution of sodium bicarbonate and a saturated aqueous solution of sodium chloride. The' solution was then dried over anhydrous sodium sulphate and the solvent was distilled off. The residue was 20 adsorbed on a column containing 10 g of silica^gel (Wakogel C-100) which had previously been treated with benzene. The fractions eluted with- a 4 : 9 6 by volume mixture of 19444 38, ethyl acetate and benzene were collected and the solvent was distilled off to give 70 mg of the benzyl ester of Monacolin K in the form of a colourless oil.
This compound had the following properties: 1. Molecular weight: 512.6 Cby mass spectrometry). 2. Molecular formula: CTlE,,-,0c 3144 6 3. Infrared absorption spectrum (CHCl^): As shown in Figure 13 of the accompanying drawings. 4.
Nuclear magnetic resonance spectrum (CDCl^): As shown in Figure 14 of the accompanying drawings.

Claims (18)

  1. I 94445 39 WHAT WE CLWM IS:- in which: R represents a metal atom or an alkyl group substituted by aryl, acyl, alkoxy, halogen or hydroxy or an unsubstituted alkyl group; and n is the reciprocal of the valency of the atom or group represented by R.
  2. 2. Monacolin K salts according to Claim 1, in which R represents a metal atom.
  3. 3. Salts according to Claim 2, in which sSid metal atom is sodium, potassium, calcium, magnesium. aluminium, iron, zinc, coppesgf^J^^ke 1 or cobalt. '94445 AO.
  4. Salts according to Claim 2, in which said is sodium, calcium or aluminium.
  5. 5. Monacolin K esters according to Claim 1, in which R represents an alkyl group substituted by aryl, acyl, alkoxy, halogen or hydroxy or an unsubstituted alkyl group and n is 1.
  6. 6. Esters according to Claim 5, in which R represents an alkyl, aralkyl or acylalkyl group.
  7. 7. Esters according to Claim 5, in which R represents an alkyl, aralkyl or arylcarbonylalkyl group.
  8. 8. Esters according to Claim 5, in which R represents an alkyl group, a benzyl group, a benzyl group having one or more alkyl, alkoxy or halogen substituents, a phenacyl group or a phenacyl group having one or more alkyl, alkoxy or halogen substituents. *
  9. 9. Esters according to Claim 5, in which R represents a methyl, ethyl, butyl or benzyl group. A. metal 194445 41.
  10. 10. a process for preparing Monacolin K salts and esters as defined in claim 1 which comprises salifying Monacolin K or the parent acid at a pH above 5, or esterifying Monacolin K or the parent acid or a Monacolin K-salt.
  11. 11. A process for preparing Monacolin K esters according to Claim 10 , in which the Monacolin K parent acid or a Monacolin K salt is esterified.
  12. 12. A process according to Claim !10, in which Monacolin K esters are prepared by reacting a halide of formula RX (wherein R represents an alkyl group substituted by aryl, acyl, alkoxy, halogen or hydroxy or an unsubstituted alkyl group and X represents a halogen atom) with a Monacolin K salt.
  13. 13. A process according to Claim 10, in which Monacolin K esters are prepared by reacting an alcohol of formula ROH (wherein R represents an alkyl group substituted by aryl, acyl, alkoxy, halogen or hydroxy or an unsubstituted alkyl group) with Monaco3|in K or its parent acid in the presence of a dehydrating'agent.
  14. 14. A process according to any one of claims 10 to 13 for preparing Monacolin K salts and esters, which comprises \ cultivating a Monacolin K-producing microorganism of the genus Monascus in a culture medium therefor and separating uil ^4// m , "onacolin K starting material from the culture medium. 194445 42.
  15. 15. A process according to Claim 14, in which said microorganism of the genus Monascus is: Monascus anka SANK 10171 (IFO 6540), Monascus purpurous SANK 10271 (IFO 4513), Monascus ruber CANK 1J571 (Ferm 4958), Monascus vitreus SANK—1QQ6Q (NIHS 609, e-609; Ferm 4960), Monascus paxii SA-T4K—11172 (IFO 6201); Monascus ruber BANK—11272 (IFO 9203), Monascus ruber SANK. 13 77B (Ferm 4959), Monascus ruber CANK 1517-7 (Ferm 4956), Monascus ruber SANK 17075 (CBS 632.70), Monascus ruber SANK—17175 (CBS 503.70), Monascus ruber SANK 17275 (ATCC 18199), or Monascus ruber SANK 16170 (Ferm 4957).
  16. 16. A process according to Claim 14, in which said microorganism is: Monascus ruber SANK—10671 (Ferm 4958), Monascus ruber SANK—11272 (IFO 9203), Monascus ruber SANK 1377B .(Ferm 4959), Monascus ruber SANK ■ 15177 (Ferm 4956); or Monascus ruber SANK—18174 (Ferm 4957).
  17. 17. A process for preparing a Monacolin salt according to any one of Claims 14 to 16, in which R is a metal atom selected from sodium, potassium, calcium, magnesium, aluminium, iron, zinc, copper, nickel or cobalt.
  18. 18. A process according to Claim 17 , in which said metal is sodium, calcium or aluminium. BALDWlM Ohm _
NZ194445A 1979-07-27 1980-07-25 Monacolin k salts and esters NZ194445A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP9581479A JPS5621594A (en) 1979-07-27 1979-07-27 Mb-530b carboxylic acid metal salt and its preparation
JP12346179A JPS5646841A (en) 1979-09-26 1979-09-26 Mb-530b carboxylic acid ester and its preparation

Publications (1)

Publication Number Publication Date
NZ194445A true NZ194445A (en) 1984-07-06

Family

ID=26436995

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ194445A NZ194445A (en) 1979-07-27 1980-07-25 Monacolin k salts and esters

Country Status (16)

Country Link
AT (1) AT375334B (en)
AU (1) AU6083980A (en)
CH (1) CH647749A5 (en)
DD (1) DD153827A5 (en)
DE (1) DE3028284A1 (en)
DK (1) DK322380A (en)
ES (1) ES493726A0 (en)
FI (1) FI71300C (en)
FR (1) FR2462417A1 (en)
GB (1) GB2055100A (en)
IT (1) IT1147763B (en)
NL (1) NL8004303A (en)
NO (1) NO156210C (en)
NZ (1) NZ194445A (en)
PL (1) PL225901A1 (en)
SE (1) SE445828B (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1327360C (en) * 1983-11-14 1994-03-01 William F. Hoffman Oxo-analogs of mevinolin-like antihypercholesterolemic agents
CA1282425C (en) * 1984-06-04 1991-04-02 Meyer Sletzinger Process for preparing hmg-coa reductase inhibitors with a 3,5-dihydroxypentanoate subunit
EP0204287A3 (en) * 1985-06-04 1987-07-01 Merck & Co. Inc. Process for the preparation of hmg-coa reductase inhibitors with a 3,5-dihydroxypentanoate subunit
US4611081A (en) * 1985-07-05 1986-09-09 Merck & Co., Inc. Process for the preparation of HMG-CoA reductase inhibitors intermediates
USRE33033E (en) * 1985-07-05 1989-08-22 Merck & Co., Inc. Process for the preparation of HMG-CoA reductase inhibitors intermediates
US6046022A (en) 1996-09-30 2000-04-04 Peking University Methods and compositions employing red rice fermentation products
US7238348B2 (en) 1996-09-30 2007-07-03 Beijing Peking University Wbl Corporation Ltd. Method of treatment of osteoporosis with compositions of red rice fermentation products
CA2335366A1 (en) * 1998-06-24 1999-12-29 Merck & Co., Inc. Compositions and methods for treating elevated blood cholesterol
SI20070A (en) 1998-09-18 2000-04-30 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. NOVEL SALTS OF INHIBITORS OF HMG-CoA REDUCTASE
US6806290B2 (en) 2000-06-09 2004-10-19 Lek Pharmaceuticals D.D. Stabilized pharmaceutically effective composition and pharmaceutical formulation comprising the same
SI1292293T1 (en) * 2000-06-09 2004-06-30 LEK farmacevtska dru�ba d.d. Stabilized pharmaceutically effective composition and pharmaceutical formulation comprising the same
AU2001288724A1 (en) * 2000-09-06 2002-03-22 Merck & Co., Inc. Dihydroxy open-acid salt of simvastatin
BR0210426A (en) 2001-06-13 2004-08-17 Ranbaxy Lab Ltd Simvastatin analogue methyl for hmg-coa reductase inhibition and process for obtaining it
KR100379075B1 (en) 2002-03-07 2003-04-08 Jinis Biopharmaceuticals Co Method for producing low cholesterol animal food product and food product therefrom
US8158362B2 (en) 2005-03-30 2012-04-17 Decode Genetics Ehf. Methods of diagnosing susceptibility to myocardial infarction and screening for an LTA4H haplotype
CN101659923B (en) * 2008-08-26 2011-10-26 北京北大维信生物科技有限公司 Method for preparing open-loop lovastatin

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4137322A (en) * 1976-11-02 1979-01-30 Sankyo Company Limited ML-236B carboxylic acid derivatives and their use as antihyperlipemic agents
JPS55150898A (en) * 1979-05-11 1980-11-25 Sankyo Co Ltd Preparation of a new physiologically active substance mb-530b

Also Published As

Publication number Publication date
DK322380A (en) 1981-01-28
DD153827A5 (en) 1982-02-03
NO156210C (en) 1987-08-12
SE8005386L (en) 1981-01-28
ES8105781A1 (en) 1981-06-16
FI71300C (en) 1986-12-19
NO802244L (en) 1981-01-28
FR2462417B1 (en) 1984-01-20
AU6083980A (en) 1981-01-29
CH647749A5 (en) 1985-02-15
AT375334B (en) 1984-07-25
ES493726A0 (en) 1981-06-16
DE3028284A1 (en) 1981-02-19
IT8068211A0 (en) 1980-07-28
FI71300B (en) 1986-09-09
GB2055100A (en) 1981-02-25
FI802357A (en) 1981-01-28
NO156210B (en) 1987-05-04
PL225901A1 (en) 1982-07-19
FR2462417A1 (en) 1981-02-13
NL8004303A (en) 1981-01-29
DE3028284C2 (en) 1990-08-09
ATA392380A (en) 1983-12-15
IT1147763B (en) 1986-11-26
SE445828B (en) 1986-07-21

Similar Documents

Publication Publication Date Title
US4323648A (en) Preparation of Monacolin K
CA1129794A (en) Antihypercholesteraemic agent, monacolin k, and its preparation
US4294926A (en) Hypocholesteremic fermentation products and process of preparation
US4231938A (en) Hypocholesteremic fermentation products and process of preparation
US4319039A (en) Preparation of ammonium salt of hypocholesteremic fermentation product
CA1046439A (en) Physiologically active substances from penicillium citrinum
US4342767A (en) Hypocholesteremic fermentation products
NZ194445A (en) Monacolin k salts and esters
CA2015940A1 (en) Antifungal agent
AU673560B2 (en) Antibiotic agents
NL8204904A (en) DIHYDRO- AND TETRAHYDROMONACOLIN L, METAL SALTS AND ALKYL ESTERS, AND METHOD FOR PREPARING THE SAME.
US5304485A (en) Antibiotic producing microorganism
WO1993017991A1 (en) TETRALIN DERIVATIVES AS HMG-CoA REDUCTASE INHIBITORS
JPS5840475B2 (en) New physiologically active substance ML-236A and its manufacturing method
JPS6113798B2 (en)
JPS6320215B2 (en)
JPS59181294A (en) Antibiotic substance ptl-448, its derivative and their preparation
CA2057651A1 (en) Agistatins, novel metabolites from fusarium sp., a process for their preparation, and their use
BE884518A (en) NOVEL MONACOLIN K DERIVATIVES, THEIR PREPARATION PROCESS AND THEIR THERAPEUTIC APPLICATION
JPS6210998B2 (en)